Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > And FDA's backlog of generics is getting heat
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by PROtradingon Sep 26, 2016 4:03pm
87 Views
Post# 25279376

RE:And FDA's backlog of generics is getting heat

RE:And FDA's backlog of generics is getting heatLot of press on this topic

https://www.forbes.com/sites/tomasphilipson/2016/05/09/speed-and-safety-at-the-fda-generic-drug-approvals-reach-record-highs/#7d25dbd0559b

smallshort wrote: And although not specifically mentioned, this aims straight at Concordia's inability to recover from its crippling debts.

FDA needs to fix its generic approval Backlog - NPR News



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities